Subscribe to Newsletter
Manufacture Business Practice, Small Molecules, Trends & Forecasts

Celebrating 200 years of history

Johnson Matthey, a global leader in science that provides cleaner air, improved health and more efficient use of natural resources, is celebrating its 200th year in existence. To mark JM’s bicentenary, the company is taking a look back at some of its biggest achievements so far within the Pharma industry. JM is well known for being responsible for the first hypodermic injection into a human in 1854, as well as pioneering aseptic surgery and, in 1870, producing the first sterile dressing. JM also played a major role in discovering and developing the platinum-based, anti-cancer drugs, carboplatin in 1975 and cisplatin in 1977, which are today among the world’s most successful cancer drug treatments. More recently, the company acquired the Pharmorphix® solid form business, bringing world-leading solid state capabilities to JM. Over the past 200 years JM has established itself as a world leader within the Pharma industry, and will continue to innovate and solve complex chemistries to enhance people’s quality of life.

Receive content, products, events as well as relevant industry updates from The Medicine Maker and its sponsors.
Stay up to date with our other newsletters and sponsors information, tailored specifically to the fields you are interested in

When you click “Subscribe” we will email you a link, which you must click to verify the email address above and activate your subscription. If you do not receive this email, please contact us at [email protected].
If you wish to unsubscribe, you can update your preferences at any point.

Register to The Medicine Maker

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Medicine Maker magazine